Stay updated with breaking news from Jamesd Berry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CNM-Au8 30mg treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo (18 months from randomization, p=0.023)60% decreased risk of long-term all-cause mortality (>18
/PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three presentations on amyotrophic lateral sclerosis (ALS) as part of the 2023...
/PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three presentations on amyotrophic lateral sclerosis (ALS) as part of the Motor...
Researchers using machine learning find neurodegenerative disease progression can fall into newly identified patterns. The work, led by members of the MIT-IBM Watson AI Lab, may help predict patient prognoses, inform clinical trial designs, and discover underlying disease causes.
A new paper in Annals of Neurology describes the approach, structure, and launch of the HEALEY ALS Platform Trial– the first platform trial for amyotrophic lateral sclerosis (ALS) designed to accelerate the development of effective and breakthrough treatments for people with the illness.